TP53 and metastatic neoplasm: Current treatments are based on prognostic factors which have led to define four risk groups: low-risk group, associated with a survival rate above 90% (mainly MB of the WNT subgroup); standard-risk group, associated with a survival rate between 75% and 90% (SHH subgroup of MB and group 4 metastatic MB); high-risk group (survival rate between 50% and 75%) and very high-risk group (MYC-amplified group 3 patients with metastatic disease or SHH tumors with TP53 mutations), both associated with a survival rate of less than 50% (in particular group 3 and SHH MB with the TP53 mutation) (39).